Long-term safety and efficacy of benralizumab in patients with severe, un-controlled asthma: 1-year results from the BORA phase 3 extension trial (vol 7, pg 46, 2019)

被引：0
|
作者：
Busse, W. W.
Bleecker, E. R.
FitzGerald, J. M.
机构：
来源：
LANCET RESPIRATORY MEDICINE | 2019年 / 7卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：E1 / E1
页数：1
相关论文
共 50 条
  • [1] Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial
    Busse, William W.
    Bleecker, Eugene R.
    FitzGerald, J. Mark
    Ferguson, Gary T.
    Barker, Peter
    Sproule, Stephanie
    Olsson, Richard F.
    Martin, Ubaldo J.
    Goldman, Mitchell
    LANCET RESPIRATORY MEDICINE, 2019, 7 (01): : 46 - 59
  • [2] Late Breaking Abstract - Long-term safety and efficacy of benralizumab in severe, uncontrolled asthma: first results of BORA, a randomized, Phase III extension study
    Busse, William W.
    Bleecker, Eugene R.
    Fitzgerald, J. Mark
    Ferguson, Gary T.
    Barker, Peter
    Sproule, Stephanie
    Olsson, Richard F.
    Goldman, Mitchell
    Martin, Ubaldo
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [3] Three-Year Safety and Efficacy of Benralizumab for Adolescent Patients with Severe, Uncontrolled Asthma: Results of the BORA Extension Study
    Busse, William
    Bleecker, Eugene
    FitzGerald, J. Mark
    Ferguson, Gary
    Barker, Peter
    Brooks, Laura
    Olsson, Richard
    Martin, Ubaldo
    Goldman, Mitchell
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB174 - AB174
  • [4] Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5-year extension of a phase 3 study (reSURFACE 1)
    Imafuku, Shinichi
    Nakagawa, Hidemi
    Igarashi, Atsuyuki
    Morita, Akimichi
    Okubo, Yukari
    Sano, Shigetoshi
    Tada, Yayoi
    Nemoto, Osamu
    Rozzo, Stephen J.
    Kawamura, Masaki
    Ohtsuki, Mamitaro
    JOURNAL OF DERMATOLOGY, 2021, 48 (06): : 844 - 852
  • [5] Safety and efficacy outcomes from the long-term extension study of tolebrutinib in patients with relapsing MS: Year 1 results
    Oh, J.
    Syed, S.
    Orogun, L.
    Matta, A.
    Dukovic, D.
    Fox, R.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 571 - 572
  • [6] Long-Term Efficacy and Safety of Lomitapide for the Treatment of Homozygous Familial Hypercholesterolemia: Results of the Phase 3 Extension Trial
    Blom, Dirk
    Averna, Maurizio
    Meagher, Emma
    Theron, Hendrik du Toit
    Sirtori, Cesare
    Hegele, Robert
    Shah, Prediman
    Gaudet, Daniel
    Stefanutti, Claudia
    Vigna, Giovanni
    Foulds, Pam
    Bloedon, LeAnne
    Rader, Daniel
    Cuchel, Marina
    CIRCULATION, 2015, 132
  • [7] Long-term efficacy and safety of 1% glycopyrronium bromide cream in patients with severe primary axillary hyperhidrosis: Results from a Phase 3b trial
    Szeimies, Rolf-Markus
    Abels, Christoph
    Kilic, Ana
    Reich, Hubert
    Berger, Birgit
    zur Wiesche, Erik Schulze
    Schramm, Katharina
    Litzka, Leonie
    Heimstaedt-Muskett, Susanne
    Masur, Clarissa
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (04) : 823 - 830
  • [8] Long-term safety and efficacy of rVIII-SingleChain in patients with severe haemophilia A: Interim results from a phase 3B extension study
    Mahlangu, J.
    Karim, F. Abdul
    Stasyshyn, O.
    Korczowski, B.
    Brainsky, A.
    Lucas, S.
    Li, Y.
    Pabinger, I.
    HAEMOPHILIA, 2019, 25 : 148 - 149
  • [9] A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension
    Kahn, Rene S.
    Silverman, Bernard L.
    DiPetrillo, Lauren
    Graham, Christine
    Jiang, Ying
    Yin, Jiani
    Simmons, Adam
    Bhupathi, Vasudev
    Yu, Bei
    Yagoda, Sergey
    Hopkinson, Craig
    McDonnell, David
    SCHIZOPHRENIA RESEARCH, 2021, 232 : 45 - 53
  • [10] Long-Term Safety and Efficacy of Voxelotor for Patients with Sickle Cell Disease: Results from an Open-Label Extension of the Phase 3 HOPE Trial
    Achebe, Maureen
    Hassab, Hoda
    Alkindi, Salam
    Brown, R. Clark Clark
    Telfer, Paul
    Biemond, Bart J.
    Gordeuk, Victor R.
    Lipato, Thokozeni
    Tonda, Margaret
    Gray, Sarah
    Howard, Joanna
    BLOOD, 2021, 138
12345